Literature DB >> 2776819

The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites.

L Hary1, M Andrejak, S Leleu, J Orfila, J P Capron.   

Abstract

We have compared in two separate studies the kinetics of ceftriaxone and cefotaxime in 8 cirrhotic patients with ascites and 8 control subjects after a single 20 min intravenous infusion of 1 g of each drug. The apparent volumes of distribution (Vz) were found to be significantly higher in cirrhotics than in control subjects (0.87, versus 0.49, l.kg-1, for cefotaxime and 0.23 versus 0.13 for ceftriaxone). The elimination kinetics of ceftriaxone were similar in the two groups. In contrast, the total and non-renal clearances of cefotaxime were reduced in cirrhotic patients. The two drugs rapidly entered the ascitic fluid. Peritoneal concentrations of ceftriaxone were higher than 7 micrograms.ml-1 from the second hour after the infusion and were 8.9 micrograms.ml-1 at 24 h. Peritoneal concentrations of cefotaxime were higher than 4 micrograms.ml-1 from 0.5 to 8 h after the infusion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776819     DOI: 10.1007/BF00637745

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage.

Authors:  J Cabrera; V Arroyo; A M Ballesta; A Rimola; J Gual; M Elena; J Rodes
Journal:  Gastroenterology       Date:  1982-01       Impact factor: 22.682

2.  Ceftriaxone: renal and biliary excretion and effect on the colon microflora.

Authors:  A Arvidsson; G Alván; B Angelin; O Borgå; C E Nord
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

3.  Secondary bacterial peritonitis in cirrhotic patients with ascites.

Authors:  P V Caralis; C L Sprung; E R Schiff
Journal:  South Med J       Date:  1984-05       Impact factor: 0.954

Review 4.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

5.  [Septicaemia and spontaneous peritonitis in the cirrhotic (author's transl)].

Authors:  N Clumeck; M Estenne; R Vanhoof; P Reding; A Cornil
Journal:  Nouv Presse Med       Date:  1979 Aug 25-Sep 3

6.  Spontaneous bacterial peritonitis.

Authors:  J C Hoefs; H N Canawati; F L Sapico; R R Hopkins; J Weiner; J Z Montgomerie
Journal:  Hepatology       Date:  1982 Jul-Aug       Impact factor: 17.425

7.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

8.  Risk factors for nephrotoxicity in patients treated with aminoglycosides.

Authors:  R D Moore; C R Smith; J J Lipsky; E D Mellits; P S Lietman
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

9.  Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.

Authors:  C Regamey
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

10.  Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections.

Authors:  J Felisart; A Rimola; V Arroyo; R M Perez-Ayuso; E Quintero; P Gines; J Rodes
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

View more
  17 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

2.  Clearance of ceftriaxone in critical care patients with acute renal failure.

Authors:  G Heinemeyer; J Link; W Weber; V Meschede; I Roots
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

3.  Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves.

Authors:  Y G Pawar; S K Sharma
Journal:  Vet Res Commun       Date:  2007-07-03       Impact factor: 2.459

Review 4.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

7.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.

Authors:  W L Hayton; J Kneer; R A Blouin; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

8.  Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  J Gómez-Jiménez; E Ribera; I Gasser; M A Artaza; O Del Valle; A Pahissa; J M Martínez-Vázquez
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

9.  Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score.

Authors:  Kazuhiko Nakaharai; Yohei Sakamoto; Kenichiro Yaita; Yukihiro Yoshimura; Shun Igarashi; Natsuo Tachikawa
Journal:  Eur J Clin Pharmacol       Date:  2016-04-28       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.